Evidence map›Paper›PMID 33427939›Full record

ReviewActa neuropathologica2021

The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease.

Billie J Matchett, Lea T Grinberg, Panos Theofilas, Melissa E Murray

Open access · hybridAbstract readReview
In one paragraph

Review in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Galanin receptor 1 expressing neurons in hippocampal-prefrontal circuitry modulate goal directed attention and impulse control.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  5. A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Celebrating neuropathology's contributions to Alzheimer's Disease Research Centers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  18. Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Billie J MatchettNeuropathology Laboratory, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.ORCID http://orcid.org/0000-0002-5941-7367
Lea T GrinbergMemory and Aging Center, Department of Neurology, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-6809-0618
Panos TheofilasMemory and Aging Center, Department of Neurology, University of California, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. Panos.Theofilas@ucsf.edu.ORCID http://orcid.org/0000-0001-9701-1352
Melissa E MurrayNeuropathology Laboratory, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Murray.Melissa@mayo.edu.ORCID http://orcid.org/0000-0001-7379-2545
University Memory and Aging Center · USJacksonville College · USMayo Clinic in Florida · US

Funding

Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI DENNIS WILLIAM DICKSON · 2019 to 2026
$33.5M
Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPR01AG060477 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lea Tenenholz Grinberg, Thomas C Neylan · 2019 to 2026
$8.2M
Linking Sleep Dysfunction to Tau-related Degeneration across AD ProgressionR01AG064314 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRINBERG, LEA TENENHOLZ, NEYLAN, THOMAS C · 2019 to 2023
$4.0M
Clinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9M
Imaging brain iron and protein aggregation with MRI for assessing Alzheimer's disease pathology and progressionR01AG070826 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI GRINBERG, LEA TENENHOLZ, LIU, CHUNLEI · 2021 to 2025
$3.3M
Brainstem connectomes related to Alzheimer's diseaseRF1AG056573 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SHI, YONGGANG · 2018 to 2018
$2.5M
Neuropathological changes underlying clinical heterogeneity in Alzheimer diseaseK24AG053435 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRINBERG, LEA TENENHOLZ · 2016 to 2025
$1.8M
The role of cell death pathways in mediating neuronal loss during the earliest stages of Alzheimer diseaseK01AG053433 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THEOFILAS, PANAGIOTIS · 2017 to 2021
$651k
NIA NIH HHS K01 AG053433NIA NIH HHS K24 AG053435NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG054449NIA NIH HHS R01 AG060477NIA NIH HHS R01 AG064314NIA NIH HHS R01 AG070826NIA NIH HHS RF1 AG056573NIA NIH HHS U01 AG057195
6 · The paper itself

Abstract

Alzheimer's disease (AD) is neuropathologically characterized by the intracellular accumulation of hyperphosphorylated tau and the extracellular deposition of amyloid-β plaques, which affect certain brain regions in a progressive manner. The locus coeruleus (LC), a small nucleus in the pons of the brainstem, is widely recognized as one of the earliest sites of neurofibrillary tangle formation in AD. Patients with AD exhibit significant neuronal loss in the LC, resulting in a marked reduction of its size and function. The LC, which vastly innervates several regions of the brain, is the primary source of the neurotransmitter norepinephrine (NE) in the central nervous system. Considering that NE is a major modulator of behavior, contributing to neuroprotection and suppression of neuroinflammation, degeneration of the LC in AD and the ultimate dysregulation of the LC-NE system has detrimental effects in the brain. In this review, we detail the neuroanatomy and function of the LC, its essential role in neuroprotection, and how this is dysregulated in AD. We discuss AD-related neuropathologic changes in the LC and mechanisms by which LC neurons are selectively vulnerable to insult. Further, we elucidate the neurotoxic effects of LC de-innervation both locally and at projection sites, and how this augments disease pathology, progression and severity. We summarize how preservation of the LC-NE system could be used in the treatment of AD and other neurodegenerative diseases affected by LC degeneration.

Indexed as

Alzheimer DiseaseAnimalsHumansLocus CoeruleusNerve DegenerationAlzheimer’s diseaseLocus coeruleusNorepinephrineSelective vulnerabilityTau

Identifiers

PMID33427939
PMCPMC8043919
OpenAlexW3120576328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.